{"id":"placebo-for-alirocumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109540","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"A placebo is a dummy treatment that has no therapeutic effect. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"Placebo does not have a pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:55.444Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT03537742","phase":"PHASE2","title":"Cardiac Allograft Vasculopathy Inhibition With Alirocumab","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-05-13","conditions":"Vasculopathy","enrollment":114},{"nctId":"NCT03207945","phase":"PHASE3","title":"Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-04-30","conditions":"Dyslipidemias, Cardiovascular Diseases, HIV Infections","enrollment":118},{"nctId":"NCT05469347","phase":"PHASE1","title":"Alirocumab in Patients with Sepsis","status":"COMPLETED","sponsor":"Jonathan Sevransky","startDate":"2023-01-04","conditions":"Sepsis","enrollment":50},{"nctId":"NCT04193306","phase":"PHASE4","title":"Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients","status":"UNKNOWN","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2019-11-18","conditions":"Cardiac Allograft Vasculopathy","enrollment":126},{"nctId":"NCT03273972","phase":"NA","title":"INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-09-07","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":30},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT03175367","phase":"PHASE2","title":"Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-10","conditions":"Hypercholesterolemia","enrollment":272},{"nctId":"NCT03344692","phase":"PHASE3","title":"Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2019-02-12","conditions":"Type2 Diabetes","enrollment":22},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT03542110","phase":"PHASE4","title":"The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial","status":"TERMINATED","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2018-08-04","conditions":"Saphenous Vein Graft Atherosclerosis","enrollment":46},{"nctId":"NCT01576484","phase":"PHASE2","title":"Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-02-28","conditions":"Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia","enrollment":58},{"nctId":"NCT01709513","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-09-30","conditions":"Hypercholesterolemia","enrollment":314},{"nctId":"NCT01604824","phase":"PHASE2","title":"A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-02-22","conditions":"Hypercholesterolemia","enrollment":23},{"nctId":"NCT02326220","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-03-31","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":62},{"nctId":"NCT03507374","phase":"EARLY_PHASE1","title":"PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis","status":"TERMINATED","sponsor":"University of Utah","startDate":"2018-10-30","conditions":"Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage","enrollment":20},{"nctId":"NCT01730053","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-11-30","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT01663402","phase":"PHASE3","title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":18924},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT03014830","phase":"PHASE1","title":"Alirocumab and Reverse Cholesterol Transport","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-06-01","conditions":"Atherosclerosis, Coronary Heart Disease","enrollment":28},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02979015","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-29","conditions":"Hypercholesterolemia","enrollment":35},{"nctId":"NCT02289963","phase":"PHASE3","title":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":199},{"nctId":"NCT01959971","phase":"PHASE1","title":"Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12","conditions":"Hypercholesterolemia","enrollment":20},{"nctId":"NCT01926782","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-09","conditions":"Hypercholesterolemia","enrollment":803},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT01812707","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Hypercholesterolemia","enrollment":100},{"nctId":"NCT01617655","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-06","conditions":"Hypercholesterolaemia","enrollment":107},{"nctId":"NCT01723735","phase":"PHASE1","title":"Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11","conditions":"Hypercholesterolemia","enrollment":79},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT01623115","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":486},{"nctId":"NCT01507831","phase":"PHASE3","title":"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Hypercholesterolemia","enrollment":2341},{"nctId":"NCT01644474","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":103},{"nctId":"NCT01644175","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":316},{"nctId":"NCT01709500","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-12","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":249},{"nctId":"NCT01288443","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":183},{"nctId":"NCT01288469","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":92},{"nctId":"NCT01266876","phase":"PHASE2","title":"Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":77},{"nctId":"NCT01730040","phase":"PHASE3","title":"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-10","conditions":"Hypercholesterolemia","enrollment":355}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":224,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for alirocumab)","genericName":"Placebo (for alirocumab)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo does not have a pharmacological effect. Used for Hyperlipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}